Mifamurtide - CAS 83461-56-7
Catalog number:
83461-56-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C59H109N6O19P
Molecular Weight:
1237.5
COA:
Inquire
Targets:
Others
Description:
Mifamurtide is a liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. It is a derivative of the mycobacterial cell wall component MDP and activates both monocytes and macrophages. It is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. It has orphan drug status for the treatment of osteosarcoma in the US and EU.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
Mepact; CGP-19835; MTP-PE; MTP-cephalin; L-MTP-PE; MLV19835
MSDS:
Inquire
1.Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH, Kwappenberg KM, Varypataki EM, Santos SJ, Kuijjer ML, Mohamed S, Wijnen JT, van Tol MJ, Cleton-Jansen AM, Egeler RM, Jiskoot W, Lankester AC, Schilham MW1. J Exp Clin Cancer Res. 2014 Mar 10;33:27. doi: 10.1186/1756-9966-33-27.
BACKGROUND: In osteosarcoma, the presence of tumor-infiltrating macrophages positively correlates with patient survival in contrast to the negative effect of tumor-associated macrophages in patients with other tumors. Liposome-encapsulated muramyl tripeptide (L-MTP-PE) has been introduced in the treatment of osteosarcoma patients, which may enhance the potential anti-tumor activity of macrophages. Direct anti-tumor activity of human macrophages against human osteosarcoma cells has not been described so far. Hence, we assessed osteosarcoma cell growth after co-culture with human macrophages.
2.The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis.
Song HJ1, Lee EK, Lee JA, Kim HL, Jang KW. Tumour Biol. 2014 Sep;35(9):8771-9. doi: 10.1007/s13277-014-2139-y. Epub 2014 May 30.
In the absence of long-term clinical trials that compare mifamurtide plus chemotherapy versus chemotherapy only for treatment of osteosarcoma, decision analysis is a useful tool that helps to determine the optimal treatment strategy. We analyzed the differences between mifamurtide plus chemotherapy versus chemotherapy only by using modeling to determine the treatment approach that results in longer life expectancy among children with osteosarcoma. We used the Markov model to compare the expected lifetime quality-adjusted life years (QALYs) between mifamurtide plus chemotherapy versus chemotherapy only. Our target cohort consisted of children with osteosarcoma. The starting age of the cohort was 12 years and cycle length was 3 months. The transition probabilities for each disease state and death were calculated using overall survival or progression free survival data from randomized controlled trials. Utility weights from scenario-based survey for 303 Korean general populations were applied to the model.
3.Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis.
Song HJ1, Lee JA2, Han E3, Lee EK4. Tumour Biol. 2015 Sep;36(9):6773-9. doi: 10.1007/s13277-015-3405-3. Epub 2015 Apr 3.
The mortality and progression rates in osteosarcoma differ depending on the presence of metastasis. A decision model would be useful for estimating long-term effectiveness of treatment with limited clinical trial data. The aim of this study was to explore the lifetime effectiveness of the addition of mifamurtide to chemotherapy for patients with metastatic and nonmetastatic osteosarcoma. The target population was osteosarcoma patients with or without metastasis. A Markov process model was used, whose time horizon was lifetime with a starting age of 13 years. There were five health states: disease-free (DF), recurrence, post-recurrence disease-free, post-recurrence disease-progression, and death. Transition probabilities of the starting state, DF, were calculated from the INT-0133 clinical trials for chemotherapy with and without mifamurtide. Quality-adjusted life-years (QALY) increased upon addition of mifamurtide to chemotherapy by 10.5 % (10.
4.NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
O'Mahony JF1, Paulden M2. Value Health. 2014 Jul;17(5):493-6. doi: 10.1016/j.jval.2013.02.014. Epub 2013 May 15.
The National Institute for Health and Clinical Excellence (NICE) recently recommended differential discounting of costs and health effects in the economic appraisal of health care interventions in certain circumstances. The recommendation was published in an amendment to NICE's Guide to the Methods of Technology Appraisal. The amendment states that differential discounting should be applied where "treatment effects are both substantial in restoring health and sustained over a very long period (normally at least 30 years)." Renewed interest in differential discounting from NICE is welcome; however, the recommendation's selective application of differential discounting raises a number of concerns. The stated criteria for applying differential discounting are ambiguous. The rationale for the selective application of differential discounting has not been articulated by NICE and is questionable. The selective application of differential discounting leads to several inconsistencies, the most concerning of which is the lower valuation of health gains for those with less than 30 years remaining life expectancy, which can be interpreted as age discrimination.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 127654-03-9 KF 13218

KF 13218
(CAS: 127654-03-9)

KF 13218, a novel pyridobenzazepinone derivative, inhibited human and bovine platelet thromboxane synthase with IC50 values of 27 +/- 5.8 nmol/l (mean +/- S.E.M...

SR9011
(CAS: 1379686-29-9)

SR9011, a synthetic REV-ERB agonist, has been found to have probable effect against sleep disorders and metabolic diseases. IC50: 790 nM and 560 nM for Rev-ErbB...

Iobenguane sulfate-I-131
(CAS: 139755-80-9)

Iobenguane is used in a scintigraphy method called Metaiodobenzylguanidine (MIBG) scan as a radiopharmaceutical. It can localize to adrenergic tissue and thus c...

CAS 53-03-2 Prednisone

Prednisone
(CAS: 53-03-2)

Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.

CAS 68497-62-1 Pramiracetam

Pramiracetam
(CAS: 68497-62-1)

Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. It is a more potent nootropic drug derived from...

CAS 509-20-6 Aconine

Aconine
(CAS: 509-20-6)

Aconine is extracted form the roots of Aconitum kusnezoffii Reichb, a derivative of Aconitine.

CAS 58546-54-6 Schisandrol B

Schisandrol B
(CAS: 58546-54-6)

Schisandrol B is one of its major active constituents of traditional hepato-protective Chinese medicine, Schisandra sphenanthera.

PBTZ169
(CAS: 1377239-83-2)

PBTZ169 is a decaprenyl-phosphoribose-epimerase (DprE1) inhibitor. DprE1 is an essential enzyme involved in the cell wall biosynthesis of Corynebacterineae. The...

CAS 2375-03-3 6A-methylprednisolone 21-hemisuccinate*sodium

6A-methylprednisolone 21-hemisuccinate*s
(CAS: 2375-03-3)

6α-Methylprednisolone 21-hemisuccinate, a derivative of prednisolone, is a kind of glucocorticoids. It has been developed for having longer half-life than that ...

CAS 22888-70-6 Silibinin

Silibinin
(CAS: 22888-70-6)

Silibinin (INN), also known as silybin, is the major active constituent of silymarin, standardized extract of the milk thistle seeds, containing mixture of flav...

CAS 1350622-33-1 kb-NB77-78

kb-NB77-78
(CAS: 1350622-33-1)

kb-NB77-78 is an analog of CID797718, which is a by-product of the synthesis of the parental compound, CID755673(PKD1 inhibitor).

THK5351 R enantiomer

THK5351 R enantiomer is an R enantiomer of THK5351 which can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain and bou...

CAS 501-68-8 Beclamide

Beclamide
(CAS: 501-68-8)

Beclamide is a chlorinated benzylpropanamide that possesses anticonvulsant activity, has been used for the treatment of tonic-clonic seizyres and has sedative p...

JNJ-2408068
(CAS: 317846-22-3)

JNJ-2408068 is a potent inhibitor of respiratory syncytial virus (RSV), exhibits potent antiviral activity with 50% effective concentrations (EC50s) of 1.4 and ...

CAS 68181-17-9 SPDP

SPDP
(CAS: 68181-17-9)

SPDP is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide...

CAS 174721-08-5 Ginsenoside Rh4

Ginsenoside Rh4
(CAS: 174721-08-5)

Ginsenoside Rh4 is a saponin isolated from the roots of Panax notoginseng (Burk.) F. H. Chen; used as adjuvant with low or non-haemolytic effect.

CAS 970-74-1 (-)-Epigallocatechin

(-)-Epigallocatechin
(CAS: 970-74-1)

(-)-Epigallocatechin is the most abundant flavonoid in green tea. It is a major green tea polyphenol with antioxidant, anti-inflammatory, and anticancer activit...

CAS 112111-44-1 (S)-(+)-Modafinic acid

(S)-(+)-Modafinic acid
(CAS: 112111-44-1)

(S)-(+)-Modafinic acid is the major metabolite of Modafinil(HY-10521A), which is a central nervous system vigilance promoting agent, which posseses neuroprotect...

Hybendazole hydrochloride
(CAS: 37975-24-9)

Hybendazole hydrochloride is a synthetic bio-active chemical.

CAS 16200-50-3 PYR-0503

PYR-0503
(CAS: 16200-50-3)

PYR-0503, a pyrrole compound, could be commonly used in production of sorts of important compounds like some anticancer drugs and porphyrins.

Chemical Structure

CAS 83461-56-7 Mifamurtide

Quick Inquiry

Verification code

Featured Items